# Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients

> **NCT07382180** · — · COMPLETED · sponsor: **Azienda Sanitaria Locale Napoli 2 Nord** · enrollment: 254 (actual)

## Conditions studied

- Obesity & Overweight
- Weight Regain
- Obesity, Morbid

## Interventions

- **DRUG:** Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician

## Key facts

- **NCT ID:** NCT07382180
- **Lead sponsor:** Azienda Sanitaria Locale Napoli 2 Nord
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-01
- **Primary completion:** 2026-01-18
- **Final completion:** 2026-01-18
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07382180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07382180, "Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07382180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*